ImmunityBio, Inc. IBRX Net Income
Net Income at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s net income?
- ImmunityBio, Inc. (IBRX) reported net income of -$632.78M in Q1 2026.
- How has ImmunityBio, Inc.'s net income changed year-over-year?
- ImmunityBio, Inc.'s net income decreased by 388.1% year-over-year, from -$129.65M to -$632.78M.
- What is the long-term trend for ImmunityBio, Inc.'s net income?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s net income has grown at a 0.3% compound annual growth rate (CAGR), from -$346.79M to -$351.4M.
- What does net income mean?
- The final profit or loss of the company after all costs and taxes are accounted for.
- How do you interpret net income?
- Positive net income indicates a profitable business, while negative net income indicates a net loss, common in growth-stage biotech.
- How does net income compare across companies?
- Standard measure of bottom-line performance used across all public companies.